Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Transfer Cellavista Business to SynenTec

NEW YORK (GenomeWeb News) – Roche today said that it will transfer its Cellavista Systems business to SynenTec, a German firm that is the original inventor of the technology.

The move is part of Roche's ongoing restructuring of its Applied Science unit, which includes shuttering its NimbleGen microarray business. As reported last month by GenomeWeb Daily News sister publication In Sequence, Roche plans to shed its Cellavista and xCELLigence cellular analysis systems, while integrating the remainder of the cell analysis business with biochemical reagents as part of the restructuring.

The Cellavista Imaging System is used for the noninvasive measurement of cell expansion and for cellular applications in cell line development, cellular research, and drug discovery.

SynenTec will take over worldwide distribution of the systems and provide application support and service. Roche will remain the primary contact for support needs until SynenTec resumes full responsibility for the systems on June 1, 2013.

Further terms of the transfer were not disclosed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.